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Research Paper
Quality of life, depression and fatigue in
mildly disabled patients with relapsing–
remitting multiple sclerosis receiving
subcutaneous interferon beta-1a: 3-year
results from the COGIMUS (COGnitive
Impairment in MUltiple Sclerosis) study
F Patti1, MP Amato2, M Trojano3, S Bastianello4, MR Tola5,
O Picconi6, S Cilia6, S Cottone7, D Centonze8 and C Gasperini9
on behalf of the COGIMUS Study Group
Abstract
Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple
sclerosis (MS) are complex and poorly understood.
Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over
3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status.
Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–
remitting MS treated with subcutaneous interferon beta-1a.
Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 mg subcutaneously three times
weekly, and 163 received interferon beta-1a, 22 mg subcutaneously three times weekly). Mean MS Quality of Life-54
(MSQoL-54) composite scores did not change over time. There were no significant differences between groups in
MSQoL-54 composite scores when patients were grouped by treatment dose and baseline cognitive status. Mean
(standard deviation) Hamilton Depression Rating Scale score decreased from 6.8 (4.9) at baseline to 5.8 (5.9) at
year 3. Mean total Fatigue Impact Scale scores were low (<30) at all time points.
Conclusion: Quality of life, depression and fatigue remained largely stable over 3 years; no effects of treatment dose or
baseline cognitive status were found.
Keywords
cognitive function, depression, fatigue, interferon beta-1a, longitudinal study, quality of life, relapsing–remitting
multiple sclerosis
Date received: 4th November 2010; revised: 23rd December 2010; 31st January 2011; accepted: 5th February 2011
Introduction
Multiple sclerosis (MS) has a signiﬁcant and ongoing
impact on patients’ health-related quality of life
(QoL).1,2 Neuropsychological symptoms, fatigue and
declining social functioning are common and contrib-
ute to the burden of disease in MS;3,4 however, routine
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patient assessment tends to concentrate on physical
disability, often leaving other symptoms and overall
QoL overlooked. Furthermore, the degree to which
patients perceive that their illness impacts on their
daily lives has an important inﬂuence on their overall
mental health.2 Depression is a common complication
of MS; the lifetime prevalence has been estimated to be
as high as 50%, which is about three times that
observed in the general population.1,5,6 In addition,
fatigue is one of the most prevalent and disabling symp-
toms associated with MS, and has been reported in as
many as 95–97% of patients.7,8 Depression and fatigue
have been identiﬁed as major determinants of impaired
QoL in MS, independent of physical disability.2,9–13
However, the precise relationships among QoL, depres-
sion and fatigue are likely to be complex and are
still poorly understood. The involvement of moderat-
ing variables to explain diverse results has been
suggested.8,14,15
Cognitive impairment is also a common feature of
MS, occurring in 20–70% of patients.1,16–18 It can
occur in early-stage MS and even in patients with clin-
ically isolated syndrome.19 Cognitive performance has
been shown to have an association with QoL in
early MS; however, interactions between cognitive
status and depression or fatigue are deemed more
complex.6,19–22
The objective of the observational COGIMUS
(COGnition Impairment in MUltiple Sclerosis patients)
study was to assess the eﬀects of subcutaneous (sc)
interferon beta-1a (IFNb-1a) on cognitive function
over 3 years in mildly disabled patients (Expanded
Disability Status Scale [EDSS] score 4.0) with relaps-
ing–remitting MS (RRMS). At baseline, cognitive
impairment was present in approximately 20% of
patients, and was weakly but consistently correlated
with MRI measures of disease.17 After 3 years on
study, the results suggested that treatment with
IFNb-1a may have cognitive beneﬁts, with the higher
dose (44mg sc three times weekly [tiw]) being more ben-
eﬁcial than the lower dose (22mg sc tiw).23
The aim of the present analysis was to assess the
eﬀects of sc IFNb-1a treatment on QoL, depression
and fatigue over 3 years in patients enrolled in the
COGIMUS study, and to examine the relationship
among longitudinal changes in QoL, depression and
fatigue, and baseline cognitive status.
Patients and methods
COGIMUS was a prospective, multicentre, observa-
tional, 3-year cohort trial assessing cognitive function
in Italian patients with RRMS treated with sc IFNb-1a.
Methodological details have been described in detail
elsewhere, and are summarized below only brieﬂy.17,23
Study population and treatment
Eligibility criteria have been described previously.17 In
brief, patients were aged 18–50 years, with a diagnosis
of RRMS (McDonald 2001 criteria) and an EDSS
score of 4.0, without severe psychiatric disorders,
including major depressive disorder (DSM-IV crite-
ria),24 and were naı¨ve to disease-modifying drug treat-
ment. All patients gave written informed consent and
all received IFNb treatment; the choice of IFNb for-
mulation and dose were at the physician’s discretion.23
As the large majority of patients in the study (459/550;
83.5%) received IFNb-1a, 44 mg sc tiw (n¼ 236
[42.9%]) or 22 mg sc tiw (n¼ 223 [40.5%]), patients
who received other IFNb treatments were excluded
from this analysis.23
Assessments
All patients underwent neuropsychological assessment
at baseline and every 12 months for 3 years.23 In the
event of relapse at the time of scheduled neuropsycho-
logical assessments, cognitive testing was delayed until
30 days after the last steroid injection. Cognitive func-
tion was assessed using Rao’s Brief Repeatable Battery
(BRB) and the Stroop Colour-Word Task (ST) for cog-
nitive domains. Patients were considered to be cogni-
tively impaired if they showed impaired performance
on at least three cognitive tests; for each cognitive
test, impaired performance was deﬁned as one standard
deviation (SD) below the mean Italian normative
values.25 As the frequency of cognitive impairment
was similar using this deﬁnition to that based on com-
parison with the ﬁfth percentile (BRB) and the 95th
percentile (ST),23 the latter analysis was not considered
necessary in the present paper.
QoL was assessed by the MSQoL-54 questionnaire,
depression by the Hamilton Depression Rating Scale
(HDRS),26 fatigue by the Fatigue Impact Scale
(FIS),27 social functioning by the Environmental
Status Scale (ESS),28 and intelligence quotient (IQ)
using the Brief Intelligence Test.29
Statistical analyses
Means, standard deviations, medians and ranges were
calculated for all numerical variables at baseline and
years 1, 2 and 3. Diﬀerences in baseline demographic
and disease characteristics between patient groups were
analysed using the Mann–Whitney test (quantitative
variables) or the chi-squared test (qualitative variables).
A Kruskall–Wallis test was performed to assess non-
parametric four-group comparisons of k independent
samples for IFNb-1a dose and presence or absence of
cognitive impairment. Changes over time between
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deﬁned groups were analysed using analysis of variance
(ANOVA) for repeated measures.
Baseline variables (e.g. age, and MSQoL-54, FIS
and EDSS scores) were evaluated as potential con-
founding variables for a given endpoint measure or
endpoint subcategory using analysis of covariance
(ANCOVA). Multiple logistic regression (multivariate
stepwise forward regression) was used to determine pre-
dictors of worsening score; a clinically relevant change
in score was deﬁned as a 0.5 – SD change from base-
line to year 3 (0.5 þ SD for ESS and its subscales).30
The signiﬁcance level was set at 0.05. There was no
imputation for missing data. All statistical analyses
were performed using SAS 9 (SAS Institute Inc.,
Cary, NC, USA) and STATA 8.2 software (Stata
Corp., College Station, TX, USA).
Results
Patients
Overall, 331/459 patients (72.1%) completed the 3-year
study: 168 received IFNb-1a, 44 mg sc tiw, and 163
received IFNb-1a, 22 mg sc tiw. Dropout rates and rea-
sons for discontinuation were similar in both dose
groups and have been described previously.23 There
were no signiﬁcant diﬀerences in baseline demographic
and disease characteristics between patients who did
and did not complete the study. Baseline demographic
characteristics in patients who completed the study by
assigned treatment dose and by baseline cognitive
status are shown in Table 1.
Quality of life
At baseline, MSQoL-54 Physical Health Composite
Score (PHCS) and Mental Health Composite Score
(MHCS) did not diﬀer between patients with and with-
out cognitive impairment. Mean baseline scores were
signiﬁcantly higher (denoting better QoL) in cognitively
impaired than cognitively preserved patients for two
MSQoL-54 subscales: ‘change in health’ (mean [SD]
score: 49.6 [25.4] vs 41.4 [2.7], p¼ 0.03) and ‘sexual
function’ (89.9 [22.0] vs 85.9 [21.9], p¼ 0.02; Mann–
Whitney test). No signiﬁcant diﬀerences were seen in
any other subscales.
In the group as a whole, PHCS and MHCS
remained stable over the course of the study. The
mean (SD) PHCS was 69.4 (15.8) at baseline and 69.7
(18.5) at year 3; MHCS was 66.1 (19.1) at baseline and
67.3 (20.0) at year 3. PHCS and MHCS were also sim-
ilar in the two treatment groups at all time points.
When PHCS or MHCS over time were analysed by
treatment group (two-group analysis; ANOVA for
repeated measures), no signiﬁcant variation over time
was seen. Similarly, there were no between-group dif-
ferences when analysed by treatment group and
presence or absence of cognitive impairment at baseline
(four-group analysis). Signiﬁcant change over 3 years
was seen in some MSQoL-54 subscales in both the two-
and four-group analysis (ANOVA for repeated mea-
sures; Figure 1). There were no signiﬁcant interactions
between changes over time and group.
Depressive symptoms
Baseline HDRS was similar in patients with (mean [SD]
score: 6.0 [4.4]) and without (7.0 [5.0]) cognitive impair-
ment at baseline (p¼ 0.25; Mann–Whitney test). Mean
[SD] HDRS score in the whole population was reason-
ably stable over the course of the study (6.8 [4.9] at
baseline and 5.8 [5.9] at year 3) and were similar in
both treatment groups at all time points (data not
shown).
The proportion of patients with depression (HDRS
score >10) decreased over time, from 82/319 (25.7%) at
baseline to 52/319 (16.3%) at year 3 (p¼ 0.005;
ANOVA). This change was seen only in the subgroup
of patients without cognitive impairment at baseline
(baseline: 72/257 [28%] patients; year 3: 48/257
[18.7%] patients, p¼ 0.003; ANOVA). HDRS score
improved signiﬁcantly over time when data were ana-
lysed by treatment group, from 6.8 at baseline to 6.3 at
year 3 in patients receiving IFNb-1a, 44 mg sc tiw, and
from 6.7 to 5.5 in patients receiving IFNb-1a, 22 mg sc
tiw (p¼ 0.006, ANOVA for repeated measures). There
was no eﬀect of treatment on this outcome (p¼ 0.48).
No signiﬁcant eﬀect of time or group was seen in the
four-group analysis.
Fatigue
Overall, FIS scores increased slightly between baseline
and year 3, although there was a large degree of varia-
tion in individual patient scores (Table 2). Mean
total FIS scores throughout the study were low (<30
at all time points) and similar in both treatment
groups (Table 2). No signiﬁcant diﬀerences over time
or between groups were seen in either the two-group
or four-group analysis (ANOVA for repeated mea-
sures). A trend towards worsening over time was seen
in the FIS cognitive subscale in all four subgroups
(p¼ 0.058).
Confounding factors
Confounding factors were identiﬁed using ANCOVA;
results for global QoL, total FIS score and HDRS score
at 3 years are shown in Table 3. As expected, there was
some overlap between factors identiﬁed for global QoL
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and for the MSQoL-54 MHCS and PHCS (i.e. baseline
HDRS and age), and for those identiﬁed for FIS sub-
scales and total score (data not shown). In addition,
total IQ was a confounder for MHCS (p¼ 0.003) and
performance IQ for PHCS (p¼ 0.01). Baseline HDRS
score was a consistent confounding factor across all
parameters assessed. Total FIS score at baseline was a
confounder for global QoL, HDRS score and total FIS
score at 3 years. Age was identiﬁed as a confounding
factor for all FIS scores except the cognitive subscale,
for which verbal IQ was a confounding factor. Each
baseline variable was also a confounding factor for
that same variable at 3 years.
Predictors of clinically important changes over time
Variables predictive of clinically important worsening
or improving scores for QoL, depression and fatigue
are shown in Table 4. Total IQ was a predictor of
better QoL outcomes, but was not a predictor of fatigue
Table 1. Baseline demographic characteristics in patients who completed the study, by treatment group and presence or absence of
baseline cognitive impairment
IFNb-1a dose, sc tiw (cognitive status) N Mean SD p valuea
Age (years) 44mg (not impaired) 143 32.5 7.9 0.006
22mg (not impaired) 124 33.1 8.2
44mg (impaired) 26 33.8 6.7
22mg (impaired) 38 37.9 7.6
Time in formal education (years) 44mg (not impaired) 143 12.7 3.4 0.794
22mg (not impaired) 124 12.4 3.6
44mg (impaired) 26 12.6 3.3
22mg (impaired) 38 12.2 3.6
Duration of disease (years) 44mg (not impaired) 143 3.4 4.2 0.608
22mg (not impaired) 124 4.3 5.3
44mg (impaired) 26 3.5 3.5
22mg (impaired) 38 3.7 4.3
Total IQb 44mg (not impaired) 141 110.5 7.3 0.085
22mg (not impaired) 121 109.8 8.2
44mg (impaired) 25 107.0 9.1
22mg (impaired) 34 106.1 10.7
HDRS score 44mg (not impaired) 142 7.0 4.6 0.632
22mg (not impaired) 124 7.0 5.5
44mg (impaired) 26 6.0 4.2
22mg (impaired) 38 6.1 4.6
FIS total score 44mg (not impaired) 142 27.2 26.8 0.713
22mg (not impaired) 124 25.4 26.6
44mg (impaired) 26 19.0 15.1
22mg (impaired) 38 25.7 23.6
QoL total score 44mg (not impaired) 142 63.7 19.4 0.698
22mg (not impaired) 124 65.6 15.5
44mg (impaired) 26 67.5 15.2
22mg (impaired) 38 65.6 15.7
EDSS score 44mg (not impaired) 143 1.8 0.9 0.663
22mg (not impaired) 124 1.8 0.9
44mg (impaired) 26 1.6 1.1
22mg (impaired) 38 1.8 1.0
aKruskall–Wallis.
bPopulation ‘average’ IQ score: 102.29
EDSS, Expanded Disability Status Scale; FIS, Fatigue Impact Scale; HDRS, Hamilton Depression Rating Scale; IFN, interferon; IQ, intelligence quotient;
QoL, quality of life; sc, subcutaneous; SD, standard deviation; tiw, three times weekly.
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(A)
(B)
Figure 1. Significant changes over time in Multiple Sclerosis Quality of Life (MSQoL)-54 subscale scores by (A) treatment group
(two-group analysis), and (B) treatment group and presence/absence of cognitive impairment at baseline (four-group analysis), analysed
by analysis of variance for repeated measures. Increasing scores indicate improved quality of life.
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or depression. Baseline total FIS score predicted for
worse QoL and fatigue, but better depressive outcomes
at study end. Higher EDSS score predicted worse QoL,
in terms of both MSQoL-54 PHCS and MHCS.
Discussion
Complex interrelationships exist among cognition,
QoL, fatigue and depression in MS,13–15,19,21 to which
both physical and psychological components may con-
tribute. In the present study of patients with mild phys-
ical disability, QoL, depression and fatigue all remained
relatively stable and outcomes were similar in both
treatment groups. Overall, patients had high QoL
scores, mild depressive symptoms, high cognitive
reserve (high IQ scores) and a high level of education.
In addition, cognitive performance at baseline did not
inﬂuence these measures: only the ‘sexual function’ and
‘change in health’ subscales of the MSQoL-54 diﬀered
signiﬁcantly between patients with and without cogni-
tive impairment. While this ﬁnding may seem unex-
pected, it may be because QoL was a subjective
assessment (patient-reported MSQoL-54) whereas
cognitive function was assessed objectively by a neuro-
psychologist. It is possible that cognitively impaired
patients were not aware of disease-related deﬁcits that
were detected by neuropsychological tests, and so those
with cognitive impairment actually reported a better
QoL than those without.
The lack of change in QoL composite scores over
3 years is noteworthy, and probably results from signif-
icant improvement or deterioration in individual sub-
scales. Comparable QoL has been reported in mildly
disabled patients and in control subjects,31 suggesting
that changes in QoL may be diﬃcult to detect in
patients with mild MS. Nonetheless, in a recent study
of patients with mild disability, worse QoL after 2 years
was found in those who discontinued treatment.32
Table 4. Variables predictive of clinically relevant changes over time in quality of life (QoL), fatigue and depression, determined by
multivariate logistic regression models
Parameter Baseline variable OR 95% CI Change
QoL Age 1.05 (1.01–1.09) Worsened
QoL 1.07 (1.04–1.10) Worsened
FIS total score 1.02 (1.01–1.04) Worsened
Total IQ score 0.96 (0.93–0.99) Improved
PHCS EDSS score 1.44 (1.04–1.99) Worsened
Total IQ score 0.96 (0.93–0.99) Improved
MHCS EDSS score 1.62 (1.14–2.30) Worsened
MHCS 1.02 (1.00–1.04) Worsened
Total IQ score 0.93 (0.89–0.96) Improved
FIS total score FIS total score 1.05 (1.03–1.07) Worsened
Time in formal education 1.22 (1.06–1.40) Worsened
HDRS score HDRS score 1.36 (1.25–1.47) Worsened
FIS total score 0.98 (0.97–0.99) Improved
CI, confidence interval; EDSS, Expanded Disability Status Scale; FIS, Fatigue Impact Scale; HDRS, Hamilton Depression Rating Scale; IQ, intelligence
quotient; MHCS, Mental Health Composite Score; OR, odds ratio; PHCS, Physical Health Composite Score.
Table 3. ANCOVA analysis showing significant confounding
variables for global MSQoL-54 score, total Fatigue Impact Scale
(FIS) score and Hamilton Depression Rating Scale (HDRS) score
at 3 years
Variable Estimate p value
Global MSQoL-54 score
Intercept 57.37 <0.0001
Age 0.40 <0.0001
Baseline HDRS score 0.50 0.007
Baseline QoL 0.38 <0.0001
Baseline FIS total score 0.09 0.02
Total FIS score
Intercept 10.92 0.0423
Age 0.42 0.005
Baseline HDRS score 0.95 0.0007
Baseline EDSS score 2.37 0.0577
Baseline FIS total score 0.55 <0.0001
HDRS score
Intercept 9.58 0.0079
Baseline HDRS score 0.52 <0.0001
Baseline EDSS score 0.65 0.0187
Baseline FIS total score 0.06 <0.0001
Total IQ score 0.09 0.005
ANCOVA, analysis of covariance; EDSS, Expanded Disability Status Scale;
IQ, intelligence quotient; MSQoL, Multiple Sclerosis Quality of Life; QoL,
quality of life.
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In addition, historical data indicate that QoL deterio-
rates over 2 years in untreated patients with RRMS,30
suggesting that our results may possibly reﬂect a pro-
tective eﬀect of sc IFNb-1a on QoL. Similarly, little
change in QoL over 1 year has been reported in patients
treated with intramuscular IFNb-1a.33 However, the
eﬀect of IFNb on QoL in MS is currently unclear;
most previous studies found that IFNb treatment
improved QoL,31,32,34,35 but in one small study wors-
ened QoL was seen.12
Patients in the present analysis had high cognitive
reserves (IQ score >102), which may have protected
against cognitive decline, as previously reported.23,36
Indeed, baseline total IQ score predicted for better
QoL, possibly reﬂecting better coping strategies or
greater employability among patients with a higher
IQ, both of which likely impact on perceived QoL.37
As higher cognitive reserves can reduce the eﬀects of
brain disease on cognition,36 this, together with any
protective eﬀects of treatment, could have helped to
preserve QoL.
Events inﬂuencing patient perception of diﬀerent
aspects of QoL will diﬀer for diﬀerent subscales. It is
interesting that the ‘cognitive function’ subscale of
MSQoL-54 deteriorated when an improvement in
neuropsychologist-assessed cognitive function in the
same study has been reported.23 As discussed above,
this discrepancy may reﬂect diﬀerences in patient-
perceived cognitive impairment, measured subjectively
using MSQoL-54, and cognitive performance mea-
sured objectively by a neuropsychologist. A patient’s
perception of cognitive performance and QoL may be
inﬂuenced by many external factors, including general
feeling of wellness and support networks, in addition
to the actual disease status. Furthermore, treatment
eﬀects on physical symptoms such as relapses could
explain the improvement in the ‘role limitation – phys-
ical’ subscale and a perceived or expected beneﬁt of
treatment may have positively aﬀected the ‘role limita-
tion – emotional’ subscale, which is inﬂuenced partly
by depression. Indeed, HDRS scores were low
throughout the study, and it is possible that the oppor-
tunity to start treatment and participate in a trial
provided some reassurance and hope for disease
control, promoting positive emotions. Consistent
with this suggestion, we found that the proportion of
patients with depression decreased over 3 years; fur-
thermore, improving access to disease-modifying drugs
has been identiﬁed as a means of enhancing QoL in
patients with MS.38 Thus, our results might reﬂect a
beneﬁcial eﬀect of treatment on emotions in patients
with MS.
Overall, our ﬁndings suggest that this patient group
did not experience signiﬁcant levels of fatigue, which
may be due to the mild nature of their physical
disability. As with QoL, fatigue in MS is a complex
issue. It has been reported that fatigue correlates with
depression but not cognitive capacity.39 In contrast, a
correlation between information processing speed and
fatigue has been reported,20 while another study found
that adjusting for depression revealed such a correla-
tion.21 Impaired attention, information processing
speed and working memory could worsen cognitive
fatigue, which may explain the trend towards worsen-
ing cognitive fatigue over time reported here.
Several confounding factors and predictors of out-
comes were identiﬁed. Depression was a confounding
factor for QoL and fatigue. Fatigue was predictive of
itself and of depression over time. Others have also
observed a relationship between fatigue and depressive
symptoms.7,8 These ﬁndings are unsurprising, as a sub-
jective measure such as QoL will inevitably be inﬂu-
enced by factors such as the patient’s mood and
energy levels. The relationships among QoL, depression
and fatigue outcomes suggest that treatment of MS-
associated depression may also improve fatigue and
QoL.7 In addition, as MS-related depression is believed
to result from brain lesions in speciﬁc loci,1,40 treatment
with disease-modifying drugs, such as IFNb, which
reduce the development of MS brain lesions, could
potentially have positive eﬀects on depression, fatigue
and QoL.
Interestingly, cognitive performance at baseline had
little impact on other outcomes over 3 years. Other
studies have also found QoL to be more strongly deter-
mined by psychological factors, including mood, than
by cognitive function,41 and have failed to ﬁnd a
correlation between QoL and cognitive function in a
similar patient population.21 It is possible that the
exclusion of patients with signiﬁcant depression inﬂu-
enced our ﬁndings; this has previously been associated
with a null correlation between cognition and
depression.14,42
The present study design has a number of limita-
tions, as discussed in detail previously.23 This was an
observational study with patients assigned to treatment
at the physician’s discretion, so there was potential for
selection bias. Only patients with mild RRMS were
included in the study, so any ﬁndings are restricted to
this MS population. A major limitation was the lack of
an untreated control group, so treatment eﬀects can
only be speculated and not conﬁrmed. QoL, depression
or fatigue data at 3 years were also missing for a
number of patients. In addition, compared with objec-
tive assessments, the subjective patient-reported assess-
ments used here could have increased the likelihood of
associations being found among depression, fatigue
and QoL. There was much variation in individual
scores for all outcomes, and analyses were not exhaus-
tive as several other factors, such as social support and
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coping, may also inﬂuence depression, cognitive func-
tion and fatigue in MS.14
In summary, QoL, depression and fatigue remained
largely stable over 3 years in this study of patients
receiving sc IFNb-1a, which could possibly reﬂect a
protective eﬀect of treatment, although this cannot be
demonstrated due to the lack of an untreated control
group. The potential beneﬁts of sc IFNb-1a on these
outcomes warrant further investigation. Treatment
dose and baseline cognitive function did not aﬀect out-
comes over 3 years. Interactions were identiﬁed among
QoL, depression and fatigue, but further studies are
needed to unravel the complex relationships between
these outcomes. Our ﬁndings support the expansion
of the deﬁnition of clinical eﬃcacy beyond relapse
rate and disability to include QoL and its constituent
factors, such as fatigue, depression and cognition,3
whereby improvement is optimal but preservation with-
out worsening is still desirable.
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